5α-还原酶抑制剂在前列腺病理生理学中的作用：抑制1型同工酶是否具有额外优势？
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?
作者信息
Goldenberg Larry, So Alan, Fleshner Neil, Rendon Ricardo, Drachenberg Darrel, Elhilali Mostafa
机构信息
Professor and Head, Department of Urologic Sciences, University of British Columbia Vancouver, BC;
出版信息
Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. doi: 10.5489/cuaj.1114.
Abstract
Normal growth and function of the prostate are contingent on the reduction of testosterone to dihydrotestosterone (DHT) by 5-alpha reductase (5-AR) enzymes types 1 and 2. It has been theorized that an overabundance of DHT may be implicated in the pathogenesis of both benign prostatic hyperplasia (BPH) and prostate cancer. Inhibitors of 5-AR such as dutasteride and finasteride may therefore have an important role in the prevention and treatment of BPH and prostate cancer. Dutasteride provides greater suppression of DHT than finasteride, thereby underlying the hypothesis that inhibition of both type 1 and type 2 would provide correspondingly greater protection than inhibition of type 2 alone. We review the potential significance of the 5-AR inhibitors in reducing the risk of prostate cancer according to the basic biology of prostate disease.
摘要
前列腺的正常生长和功能取决于1型和2型5α还原酶（5-AR）将睾酮还原为二氢睾酮（DHT）。理论上，DHT过多可能与良性前列腺增生（BPH）和前列腺癌的发病机制有关。因此，5-AR抑制剂如度他雄胺和非那雄胺可能在BPH和前列腺癌的预防和治疗中发挥重要作用。度他雄胺比非那雄胺对DHT的抑制作用更强，从而支持了这样一种假设，即抑制1型和2型5-AR比单独抑制2型能提供更大的保护。我们根据前列腺疾病的基础生物学知识，综述5-AR抑制剂在降低前列腺癌风险方面的潜在意义。
相似文献
1
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?
Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. doi: 10.5489/cuaj.1114.
2
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
World J Urol. 2002 Apr;19(6):413-25. doi: 10.1007/s00345-002-0248-5.
3
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Eur Urol. 2000 Apr;37(4):367-80. doi: 10.1159/000020181.
4
[Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Urologe A. 2002 Sep;41(5):412-24. doi: 10.1007/s00120-002-0230-2.
5
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
J Clin Endocrinol Metab. 2004 May;89(5):2179-84. doi: 10.1210/jc.2003-030330.
6
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Epub 2008 Feb 20.
7
Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Clin Endocrinol (Oxf). 1997 Feb;46(2):137-44. doi: 10.1046/j.1365-2265.1997.950908.x.
8
New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Biochimie. 2013 Nov;95(11):2097-106. doi: 10.1016/j.biochi.2013.07.023. Epub 2013 Aug 9.
9
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016.
10
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
J Urol. 2004 Oct;172(4 Pt 1):1399-403. doi: 10.1097/01.ju.0000139539.94828.29.
引用本文的文献
1
The Impact of Body Mass Index and Benign Prostatic Hyperplasia on Bone Health of Middle-Aged and Older Men.
Obes Sci Pract. 2025 Jan 8;11(1):e70037. doi: 10.1002/osp4.70037. eCollection 2025 Feb.
2
Extract Alleviates Progression of Benign Prostatic Hyperplasia via Modification of Proliferation, Apoptosis, and Inflammation.
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1032. doi: 10.3390/ph17081032.
3
Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
World J Mens Health. 2025 Jan;43(1):188-196. doi: 10.5534/wjmh.230327. Epub 2024 May 20.
4
Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats.
BMC Complement Med Ther. 2021 Dec 20;21(1):301. doi: 10.1186/s12906-021-03472-2.
5
Resveratrol Attenuates the Proliferation of Prostatic Stromal Cells in Benign Prostatic Hyperplasia by Regulating Cell Cycle Progression, Apoptosis, Signaling Pathways, BPH Markers, and NF- κB Activity.
Int J Mol Sci. 2021 May 31;22(11):5969. doi: 10.3390/ijms22115969.
6
Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment.
Int Braz J Urol. 2020 May-Jun;46(3):456-458. doi: 10.1590/S1677-5538.IBJU.2020.03.02.
7
Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.
Transl Androl Urol. 2019 Oct;8(5):529-539. doi: 10.21037/tau.2019.10.01.
8
The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Urology. 2018 Sep;119:70-78. doi: 10.1016/j.urology.2018.05.033. Epub 2018 Jun 12.
9
Links between lower urinary tract symptoms, intermittent hypoxia and diabetes: Causes or cures?
Respir Physiol Neurobiol. 2018 Oct;256:87-96. doi: 10.1016/j.resp.2017.09.009. Epub 2017 Sep 18.
10
A Review of the Potential of Phytochemicals from (Hook f.) Kalkman Stem Bark for Chemoprevention and Chemotherapy of Prostate Cancer.
Evid Based Complement Alternat Med. 2017;2017:3014019. doi: 10.1155/2017/3014019. Epub 2017 Feb 13.
本文引用的文献
1
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.
2
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Expert Rev Anticancer Ther. 2008 Jul;8(7):1073-9. doi: 10.1586/14737140.8.7.1073.
3
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016.
4
Androgens and the molecular epidemiology of prostate cancer.
Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):261-70. doi: 10.1097/MED.0b013e3282febcf6.
5
The role of testosterone in the pathogenesis of prostate cancer.
Int J Urol. 2008 Jun;15(6):472-80. doi: 10.1111/j.1442-2042.2008.02074.x. Epub 2008 Apr 22.
6
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.
7
Role of 5 alpha-reductase inhibitors in the management of prostate cancer.
Clin Interv Aging. 2006;1(4):425-31. doi: 10.2147/ciia.2006.1.4.425.
8
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Eur Urol. 2008 Feb;53(2):244-52. doi: 10.1016/j.eururo.2007.10.052. Epub 2007 Nov 5.
9
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
J Urol. 2008 Jan;179(1):147-51. doi: 10.1016/j.juro.2007.08.155. Epub 2007 Nov 13.
10
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
Cancer Sci. 2008 Jan;99(1):81-6. doi: 10.1111/j.1349-7006.2007.00656.x. Epub 2007 Nov 6.
Zotero 插件